These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29735789)

  • 1. Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans.
    Beck KR; Kim NJ; Khalili M
    Ann Hepatol; 2018; 17(3):413-418. PubMed ID: 29735789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics.
    Schaeffer S; Khalili M
    Ann Hepatol; 2015; 14(2):234-42. PubMed ID: 25671833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.
    Benhammou JN; Dong TS; May FP; Kawamoto J; Dixit R; Jackson S; Dixit V; Bhattacharya D; Han SB; Pisegna JR
    Pharmacol Res Perspect; 2018 Apr; 6(2):e00379. PubMed ID: 29484189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.
    Marcus JL; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Lam JO; Pauly MP; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ
    Public Health Rep; 2018; 133(4):452-460. PubMed ID: 29750893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era.
    Shaikh A; Goli K; Lee TH; Rich NE; Benhammou JN; Keeling S; Kim D; Ahmed A; Goss J; Rana A; Singal AG; Kanwal F; Cholankeril G
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2288-2297.e4. PubMed ID: 36521738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Race and Hepatitis C Care Continuum in an Underserved Birth Cohort.
    Kim NJ; Locke CJ; Park H; Magee C; Bacchetti P; Khalili M
    J Gen Intern Med; 2019 Oct; 34(10):2005-2013. PubMed ID: 30238404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver transplantation for hepatitis C patients in the era of direct-acting antiviral treatment: A retrospective cohort study.
    Khan AS; Adams N; Vachharajani N; Dageforde L; Wellen J; Shenoy S; Crippin JS; Doyle MB; Chapman WC
    Int J Surg; 2020 Mar; 75():84-90. PubMed ID: 32014598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
    Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
    Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database.
    Tanaka T; Voigt MD
    J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):393-400. PubMed ID: 31211912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation.
    Emamaullee JA; Bral M; Meeberg G; Montano-Loza AJ; Bain VG; Burak KW; Bigam D; Shapiro AMJ; Kneteman N
    Can J Gastroenterol Hepatol; 2019; 2019():2509059. PubMed ID: 30775356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
    Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
    Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus Infection Outcomes Among Immigrants to Canada: A Retrospective Cohort Analysis.
    Cooper CL; Thavorn K; Damian E; Corsi DJ
    Ann Hepatol; 2017; 16(5):720-726. PubMed ID: 28809741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals.
    Young K; Liu B; Bhuket T; Wong RJ
    J Clin Exp Hepatol; 2020; 10(6):581-589. PubMed ID: 33311895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
    Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
    Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort.
    Kauffman-Ortega E; Ruiz-Manriquez J; Olivas-Martinez A; Campos-Murguía A; Flores-García NC; Márquez-Guillén E; López-Yáñez S; Sánchez-Ávila F; Toapanta-Yanchapaxi L; Paez-Zayas VM; García-Juárez I
    Arch Med Res; 2021 Oct; 52(7):713-718. PubMed ID: 33966917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial Disparities in Hepatitis C Treatment Eligibility.
    Sims OT; Pollio DE; Hong BA; North CS
    Ann Hepatol; 2017; 16(4):530-537. PubMed ID: 28611273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C.
    Yoo ER; Perumpail RB; Cholankeril G; Jayasekera CR; Ahmed A
    Telemed J E Health; 2017 Oct; 23(10):870-873. PubMed ID: 28375820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retransplantation outcomes for hepatitis C in the United States before and after direct-acting antiviral introduction.
    Ivanics T; Rizzari M; Moonka D; Al-Kurd A; Delvecchio K; Kitajima T; Elsabbagh AM; Collins K; Yoshida A; Abouljoud M; Nagai S
    Am J Transplant; 2021 Mar; 21(3):1100-1112. PubMed ID: 32794649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study.
    Jiménez-Romero C; Justo I; Marcacuzco A; García V; Manrique A; García-Sesma Á; Calvo J; Fernández I; Martín-Arriscado C; Caso Ó
    Int J Surg; 2021 Jul; 91():105981. PubMed ID: 34098075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.